CREST2试验强化危险因素治疗的基本原理、设计与实施
CREST2试验比较强化药物治疗(IMM) alone与IMM联合颈动脉内膜剥脱术或经股动脉颈动脉支架置入术,预防随机化后44天内卒中或死亡及此后同侧缺血性卒中。本文描述IMM方案:阿司匹林325 mg/日,主要目标收缩压<130 mm Hg、LDL<70 mg/dL。1618例患者基线至24个月随访,LDL均值从80.5降至66.7 mg/dL,收缩压均值从139.7降至130.3 mm Hg,达标率显著提高。
要点
- IMM包括阿司匹林325 mg/日及强化危险因素管理,主要目标收缩压<130 mm Hg、LDL<70 mg/dL。
- 1618例患者基线至24个月,LDL均值从80.5降至66.7 mg/dL,收缩压均值从139.7降至130.3 mm Hg。
- 收缩压<130 mm Hg达标率从43%升至61%,LDL<70 mg/dL达标率从45%升至67%(均P<0.001)。
核心结论
- CREST2试验中严格的多模式强化危险因素管理显著改善了危险因素控制,为比较先进药物治疗与血运重建在无症状颈动脉狭窄患者中的效果奠定基础。
研究设计与样本
- CREST2试验比较IMM alone与IMM联合颈动脉内膜剥脱术或经股动脉颈动脉支架置入术,主要结局为随机化后44天内卒中或死亡及此后同侧缺血性卒中。
- 本文报告1618例患者基线及截至24个月末次随访的危险因素数据。
- IMM由站点人员实施,包括阿司匹林325 mg/日、强化危险因素管理及电话生活方式指导。
主要发现
- 基线LDL均值80.5 mg/dL改善至66.7 mg/dL,基线收缩压均值139.7 mm Hg改善至130.3 mm Hg。
- 收缩压<130 mm Hg达标比例从43%提高至61%,LDL<70 mg/dL达标比例从45%提高至67%(两项变化P<0.001)。
关键数值与推荐
- IMM主要目标:收缩压<130 mm Hg(初始为<140 mm Hg),LDL<70 mg/dL。
- IMM包括阿司匹林325 mg/日。
- 次要危险因素目标聚焦吸烟、非HDL、HbA1c、体力活动和体重。
临床怎么用
- 对无症状颈动脉狭窄患者,可采用阿司匹林325 mg/日联合强化危险因素管理,以收缩压<130 mm Hg和LDL<70 mg/dL为主要目标。
局限性
- 本文报告的是中期危险因素数据,非最终临床结局比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The CREST2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis) is comparing intensive medical management (IMM) alone to IMM plus revascularization with carotid endarterectomy or transfemoral carotid artery stenting for preventing stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter. There are extensive clinical trial data on outcomes after revascularization of asymptomatic carotid stenosis, but not for IMM. As such, the experimental treatment in CREST2 is IMM, which is described in this article. METHODS: IMM consists of aspirin 325 mg/day and intensive risk factor management, primarily targeting systolic blood pressure <130 mm Hg (initially systolic blood pressure <140 mm Hg) and LDL (low-density lipoprotein) cholesterol <70 mg/dL. Secondary risk factor targets focus on tobacco smoking, non-HDL (high-density lipoprotein), HbA1c (hemoglobin A1c), physical activity, and weight. Risk factor management is performed by site personnel and a lifestyle coaching program delivered by telephone. We report interim risk factor data on 1618 patients at baseline and last follow-up through 24 months. RESULTS: The mean baseline LDL of 80.5 mg/dL improved to 66.7 mg/dL. The mean baseline systolic blood pressure of 139.7 mm Hg improved to 130.3 mm Hg. The proportion of patients in-target improved from 43% to 61% for systolic blood pressure <130 mm Hg and from 45% to 67% for LDL<70 mg/dL (both changes P<0.001). CONCLUSIONS: The rigorous multimodal approach to intensive stroke risk factor management in CREST2 has resulted in significant improvements in risk factor control that will enable a comparison of cutting-edge medical care to revascularization in patients with asymptomatic carotid stenosis. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02089217.
引用
- Turan TN, Voeks JH, Chimowitz MI, et al. Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. Stroke. 2020. PMID: 32951538. doi:10.1161/STROKEAHA.120.030730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。